318 filings
Page 11 of 16
8-K
ubafvnj mme2o8
28 Jan 13
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
12:00am
424B5
iga03si6bk2mgpd8
24 Jan 13
Prospectus supplement for primary offering
12:00am
8-K
4giux2f qfx
21 Dec 12
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
lt1eux3bbil39ss
13 Nov 12
Other Events
12:00am
424B5
5kz4 p7vwjig35cxn2
8 Nov 12
Prospectus supplement for primary offering
12:00am
8-K
l5i90nb9308i90tif
8 Nov 12
Entry into a Material Definitive Agreement
12:00am
8-K
gzn4dmilq79sv
25 Oct 12
Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results and Provides Clinical Progress Update
12:00am
8-K
r0jaztw5hpewmzq
2 Oct 12
Submission of Matters to a Vote of Security Holders
12:00am
PRE 14A
lrg3eqg
10 Aug 12
Preliminary proxy
12:00am
8-K
g4v60552h53ghrgzmh
7 Aug 12
Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results and Provides Clinical Progress Update
12:00am
424B5
3fakma4 f9w2wya
20 Jul 12
Prospectus supplement for primary offering
12:00am
8-K
q38xtxt
20 Jul 12
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
12:00am
424B5
7burlx8zum84hp4e0
18 Jul 12
Prospectus supplement for primary offering
12:00am
8-K
8ipb 3l54eqrl2aa32h
17 Jul 12
Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
12:00am
8-K
648b06qeqn0vh9j jkj
28 Jun 12
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
12:00am
8-K
xlkovmwu1eshv4h
9 May 12
Departure of Directors or Certain Officers
12:00am